1
项与 MVA-C with gp140/MF59(HIV Vaccine Trials Network) 相关的临床试验A Phase 1 Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of SAAVI DNA-C2, SAAVI MVA-C and Novartis Subtype C gp140 With MF59 Adjuvant in Various Vaccination Schedules in HIV-uninfected Healthy Vaccinia-naïve Adult Participants in South Africa
Sub-Saharan Africa is the region most affected by the global Human Immunodeficiency Virus (HIV) epidemic. A vaccine is the most promising preventive approach against new HIV infections. The purpose of this study is to evaluate the safety and immunogenicity of 4 experimental preventive HIV vaccine regimens in HIV-uninfected adults in South Africa.
100 项与 MVA-C with gp140/MF59(HIV Vaccine Trials Network) 相关的临床结果
100 项与 MVA-C with gp140/MF59(HIV Vaccine Trials Network) 相关的转化医学
100 项与 MVA-C with gp140/MF59(HIV Vaccine Trials Network) 相关的专利(医药)
100 项与 MVA-C with gp140/MF59(HIV Vaccine Trials Network) 相关的药物交易